TJPC's subsidiary has obtained the drug registration certificate for Butorphanol Tartrate Injection
I'm PortAI, I can summarize articles.
TJPC's subsidiary Tianjin Jiayuan Peace Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for Butorphanol Tartrate Injection issued by the National Medical Products Administration. This drug is mainly used for the treatment of cancer pain and postoperative pain, and it falls under the category of second-class psychotropic drugs. Jiayuan Peace submitted the registration application in October 2023 and received the certificate in October 2025, with a total R&D investment of approximately 22 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments